PMID- 35103456
OWN - NLM
STAT- Publisher
LR  - 20240220
IS  - 2724-6116 (Electronic)
IS  - 2724-6116 (Linking)
DP  - 2022 Feb 1
TI  - The effectiveness and safety of linagliptin within elderly type 2 diabetes 
      mellitus: a meta-analysis and systematic review.
LID - 10.23736/S2724-6507.22.03661-2 [doi]
AB  - BACKGROUND: Linagliptin is a convenient and effective drug approved for glycemic 
      management in type 2 diabetes mellitus (T2DM). However, the effectiveness and 
      safety evidence of linagliptin remains unclear with the increasing prevalence of 
      T2DM in elderly patients. OBJECTIVE: For evaluating the effectiveness and safety 
      of linagliptin within T2DM cases who aged >/=60 years. METHODS: The researchers 
      pooled 4903 cases aged >/=60 years with T2DM from 5 published randomized clinical 
      trials obtained from multiple databases. The safety was evaluated by the 
      incidence and severity of adverse events (AEs) which mainly focused on 
      hypoglycaemia. The major effectiveness end point was the change of glycated 
      haemoglobin (HbA1c). Then the researchers made the qualitative and quantitative 
      assessments of the investigation. RESULTS: The level of HbA1c and FPG was 
      significantly reduced by linagliptin (WMD=-0.63%, 95% CI: -0.81, -0.44; 
      p<0.00001; Z=6.70) and (WMD=-15.58 mg/dL, 95% CI: -22.34, -8.82; p<0.00001; 
      Z=4.52) relative to that in the placebo cohort. The incidences of overall 
      (OR=1.01, 95% CI: 0.82, 1.25; p=0.91) and severe negative events (OR=0.88, 95% 
      CI: 0.61, 1.25; p=0.46) were not significant increased in linagliptin cohorts 
      compared to the placebo cohorts. There is insignificant difference in 
      hypoglycaemia between linagliptin and placebo cohorts for the 24 weeks' 
      study(OR=1.12, 95% CI: 0.85, 1.48; p=0.41). Severe hypoglycemia had slightly 
      descended incidence, whereas insignificant difference was shown in the 
      linagliptin cohorts in contrast to placebo cohorts (OR=0.95, 95 % CI: 0.68, 1.32, 
      p=0.76). CONCLUSIONS: Linagliptin is an effective drug with excellent safety for 
      elderly T2DM.
FAU - Wang, Meng-Jun
AU  - Wang MJ
AD  - Department of Endocrinology, .521 Hospital of Norinco Group, Xi'an, China.
FAU - Liu, Jun-Liang
AU  - Liu JL
AD  - Department of Endocrinology, .521 Hospital of Norinco Group, Xi'an, China.
FAU - Wang, Ning
AU  - Wang N
AD  - Department of Endocrinology and Second Department of Geriatrics, The First 
      Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Han, Xuemei
AU  - Han X
AD  - Department of Endocrinology, .521 Hospital of Norinco Group, Xi'an, China.
FAU - Zhang, Hai-Xiong
AU  - Zhang HX
AD  - Department of Endocrinology, .521 Hospital of Norinco Group, Xi'an, China - 
      zhanghaixiong521@126.com.
LA  - eng
PT  - Journal Article
DEP - 20220201
PL  - Italy
TA  - Minerva Endocrinol (Torino)
JT  - Minerva endocrinology
JID - 101777342
SB  - IM
EDAT- 2022/02/02 06:00
MHDA- 2022/02/02 06:00
CRDT- 2022/02/01 10:27
PHST- 2022/02/01 10:27 [entrez]
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
AID - S2724-6507.22.03661-2 [pii]
AID - 10.23736/S2724-6507.22.03661-2 [doi]
PST - aheadofprint
SO  - Minerva Endocrinol (Torino). 2022 Feb 1. doi: 10.23736/S2724-6507.22.03661-2.